Committed to evolving our research for patients with Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) are a group of rare diseases of the blood and bone marrow that generally affect patients older than 65. MDS is considered a blood cancer. In MDS patients, genetic mutations in blood cells prevent them from fully maturing, causing them to overcrowd the bone marrow or die off. This results in an abnormally low number of healthy, mature blood cells in circulation. These low blood cell counts, or cytopenias, are a defining effect of MDS and the cause of many debilitating symptoms including infection, anemia, bleeding, and easy bruising.
Approximately 97,000 people in the US and more than 150,000 in the US and EU combined are currently living with MDS. About 18,000 new patients are diagnosed each year. Currently, there is no cure other than a stem cell transplant, and the average survival rate is about 6 years. Celgene is dedicated to advancing the research and continuously supporting patients living with MDS.
Advocacy & Collaboration
Celgene remains committed to making advancements helping to improve the lives of patients with MDS and other hematologic malignancies: Bolder Science: Myelodysplastic-Syndromes
Celgene is currently developing materials to connect patients and their caregivers with educational and practical resources.